Pharmacogenomics in Rural and Underserved Populations
This subaward from the Northwest-Alaska Pharmacogenomics Research Network at the University of Washington will study how the genetics and diet of Yup’ik people affect the anticoagulation properties of warfarin, a common drug used to treat heart disease and stroke patients.
CANHR researchers are also exploring how polyunsaturated fatty acids and vitamin K interact with warfarin to modify drug efficacy. Results from this study may help physicians determine a safe and effective dosage of this medication for this population.
Ken Thummel, Ph.D., Principal Investigator, University of Washington
Wylie Burke, M.D., Ph.D., Principal Investigator, University of Washington
Bert Boyer, Ph.D., CANHR, UAF, Principal Investigator (Subaward)
NIH/Pharmacogenomics Research Network, U01GM092676